Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Profit After Tax (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Profit After Tax for 13 consecutive years, with $61.0 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 493.02% to $61.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $105.9 million through Dec 2025, up 287.7% year-over-year, with the annual reading at $105.9 million for FY2025, 287.7% up from the prior year.
  • Profit After Tax for Q4 2025 was $61.0 million at Theravance Biopharma, up from $3.6 million in the prior quarter.
  • The five-year high for Profit After Tax was $61.0 million in Q4 2025, with the low at -$86.5 million in Q1 2021.
  • Average Profit After Tax over 5 years is -$16.9 million, with a median of -$14.9 million recorded in 2022.
  • The sharpest move saw Profit After Tax plummeted 82.46% in 2024, then surged 493.02% in 2025.
  • Over 5 years, Profit After Tax stood at -$32.0 million in 2021, then skyrocketed by 55.5% to -$14.3 million in 2022, then skyrocketed by 40.31% to -$8.5 million in 2023, then tumbled by 82.46% to -$15.5 million in 2024, then soared by 493.02% to $61.0 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at $61.0 million, $3.6 million, and $54.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.